Document Detail

Patients at high risk of invasive fungal infections: when and how to treat.
MedLine Citation:
PMID:  18778118     Owner:  NLM     Status:  MEDLINE    
When and how to treat invasive fungal infections (IFIs) is discussed in this review, with a focus on the two most prevalent non-endemic IFIs, namely invasive aspergillosis and invasive candidiasis. Early treatment initiation in patients with IFIs has a profound impact on mortality rates, but reliable diagnostic measures are lacking. This situation has led to the parallel use of different treatment strategies, e.g. prophylaxis, empirical and pre-emptive treatment, as well as targeted treatment in response to a definite diagnosis of IFI. Identifying high-risk patients is the first step in reducing IFI-related mortality. Patients at risk of invasive aspergillosis comprise (i) those with acute myelogenous leukaemia (AML) or myelodysplastic syndrome (MDS) during remission induction chemotherapy; (ii) patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT); (iii) recipients of solid organ transplants; and (iv) those with other conditions of severe and prolonged immunosuppression. Patients at high risk of invasive candidiasis are less well defined. Risk factors are diverse and include haematological malignancy, neutropenia, age <1 month or >65 years, and recent abdominal surgery. The individual risk further depends on the presence of a variety of other risk factors, including central venous catheters, use of broad spectrum antibacterials, prolonged intensive care unit (ICU) stay, total parenteral nutrition, mucosal Candida spp. colonization and renal failure.Extensive research has been conducted to facilitate the best possible treatment strategies for these severe infections. Optimal timing and choice of antifungal agents largely remain a matter of controversy. After having reviewed the major clinical trials, we conclude that comparisons between different treatment strategies cannot be made, neither at present nor in the near future. The complexity of the clinical problem leads to an eclectic treatment approach to reduce morbidity and mortality from IFIs without compromising tolerability. We recommend prophylaxis with posaconazole for allogeneic HSCT recipients, patients receiving induction chemotherapy for AML or MDS, and those undergoing immunosuppressive therapy for graft-versus-host disease after allogeneic HSCT. For the empirical treatment of persistently febrile neutropenia, caspofungin is our first- and liposomal amphotericin B deoxycholate (LAmB) our second-line choice. Once a diagnosis of invasive aspergillosis has been established, voriconazole should be the preferred treatment option, with LAmB being an alternative. Fluconazole prophylaxis for invasive candidiasis should remain restricted to high-risk ICU patients. Once a diagnosis has been established, the drug of choice for adequate treatment depends largely on neutrophil count and haemodynamic stability. In non-neutropenic patients, an echinocandin should be considered the first-line treatment option, while patients with susceptible Candida spp. may be switched to fluconazole. In neutropenic patients, caspofungin or micafungin might be preferred to anidulafungin as first-line treatment. LAmB is a second-line treatment option in both settings.Early diagnosis of IFIs is imperative to facilitate treatment success. In all patients at risk for IFIs, blood cultures, galactomannan antigen and diagnostic imaging should be rigorously enforced.
Maria J G T Rüping; Jörg J Vehreschild; Oliver A Cornely
Related Documents :
1969198 - Itraconazole in onychomycosis. open and double-blind studies.
1090988 - Aerosol chemotherapy in bronchopulmonary candidiasis.
8173148 - Use of antifungal therapy in hospitalized patients. ii. results after the marketing of ...
20647128 - Oral candidiasis in patients receiving radiation therapy for head and neck cancer.
8607958 - The effect of gastroesophageal reflux on laryngotracheal reconstruction.
17216528 - Successful treatment of cervical myelopathy with minimal morbidity by circumferential d...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Drugs     Volume:  68     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2008  
Date Detail:
Created Date:  2008-09-09     Completed Date:  2009-01-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1941-62     Citation Subset:  IM    
Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of the University of Cologne, Cologne, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifungal Agents / therapeutic use*
Aspergillosis / drug therapy,  pathology
Candidiasis / drug therapy,  pathology
Clinical Trials as Topic
Intensive Care
Mycoses / diagnosis,  drug therapy*,  epidemiology,  microbiology*,  prevention & control*
Neutropenia / complications
Reg. No./Substance:
0/Antifungal Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacological management of epilepsy: recent advances and future prospects.
Next Document:  Use of somatostatin analogues in obesity.